Literature DB >> 16996590

Genetic variation in ICOS regulates mRNA levels of ICOS and splicing isoforms of CTLA4.

Tanja Kaartinen1, Jani Lappalainen, Katri Haimila, Matti Autero, Jukka Partanen.   

Abstract

Genetic and functional studies suggest that polymorphism in cytotoxic T lymphocyte-associated antigen-4 (CTLA4) and inducible costimulator (ICOS) genes, both reported to harbour autoimmune susceptibility loci, could regulate the immune activation through affecting their expression and splicing of CTLA4. To address this, we studied expression of CTLA4 and ICOS and the role of polymorphisms in the gene region by measuring the relative amounts of transcripts, including the soluble CTLA4 (sCTLA4) splicing isoform in healthy volunteers. We combined a physiologically relevant in vitro activation for human CD4(+) T lymphocytes and a quantitative RT-PCR. The susceptibility allele CT60G in CTLA4 gene was confirmed to be associated with a decreased amount of sCTLA4, but only in resting cells. During the T cell activation two genetic variants in ICOS gene, IVS1+173T/C and c.1624C/T, affected expression of CTLA4 isoforms and ICOS, respectively. We could not confirm that the level of sCTLA4 is down-regulated following T lymphocyte activation, instead the levels of CTLA4 splicing isoforms correlated to each others. Our results indicate that genetic variation in this gene region regulates the expression of both CTLA4 and ICOS and not only the splicing of sCTLA4 as suggested earlier.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16996590     DOI: 10.1016/j.molimm.2006.08.010

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  8 in total

1.  ICOS Gene Polymorphisms (IVS1 + 173 T/C and c. 1624 C/T) in Primary Sjögren's Syndrome Patients: Analysis of ICOS Expression.

Authors:  José Antonio García-Espinoza; José Francisco Muñoz-Valle; Mariel García-Chagollán; Jorge Hernández-Bello; Claudia Azucena Palafox-Sánchez; Erika Fabiola López-Villalobos; Gabriela Athziri Sánchez-Zuno; Gloria Esther Martínez-Bonilla; Sergio Cerpa-Cruz; Francisco Josue Carrillo-Ballesteros; Edith Oregon-Romero
Journal:  Curr Issues Mol Biol       Date:  2022-02-02       Impact factor: 2.976

2.  Differential inhibition of autoreactive memory- and alloreactive naive T cell responses by soluble cytotoxic T lymphocyte antigen 4 (sCTLA4), CTLA4Ig and LEA29Y.

Authors:  V A L Huurman; W W J Unger; B P C Koeleman; M K Oaks; A K Chandraker; O T Terpstra; B O Roep
Journal:  Clin Exp Immunol       Date:  2007-10-09       Impact factor: 4.330

3.  CTLA4CT60 gene polymorphism is not associated with differential susceptibility to pemphigus foliaceus.

Authors:  Márcia Regina Pincerati; Ricardo Dalla-Costa; Maria Luiza Petzl-Erler
Journal:  Genet Mol Biol       Date:  2010-09-01       Impact factor: 1.771

4.  ICOS gene polymorphisms are associated with sporadic breast cancer: a case-control study.

Authors:  Fengyan Xu; Dalin Li; Qiujin Zhang; Zhenkun Fu; Jie Zhang; Weiguang Yuan; Shuang Chen; Da Pang; Dianjun Li
Journal:  BMC Cancer       Date:  2011-09-15       Impact factor: 4.430

Review 5.  The soluble CTLA-4 receptor and its role in autoimmune diseases: an update.

Authors:  Daniele Saverino; Rita Simone; Marcello Bagnasco; Giampaola Pesce
Journal:  Auto Immun Highlights       Date:  2010-11-04

6.  CD28/CTLA-4/ICOS haplotypes confers susceptibility to Graves' disease and modulates clinical phenotype of disease.

Authors:  Edyta Pawlak-Adamska; Irena Frydecka; Marek Bolanowski; Anna Tomkiewicz; Anna Jonkisz; Lidia Karabon; Anna Partyka; Oskar Nowak; Marek Szalinski; Jacek Daroszewski
Journal:  Endocrine       Date:  2016-09-16       Impact factor: 3.633

7.  Lack of association between sCTLA-4 levels in human plasma and common CTLA-4 polymorphisms.

Authors:  Andrew Berry; Matt Tector; Martin K Oaks
Journal:  J Negat Results Biomed       Date:  2008-11-12

8.  Chromosome 2q33genetic polymorphisms in Tunisian endemic pemphigus foliaceus.

Authors:  Olfa Abida; Emna Bahloul; Mariem Ben Jmaa; Khadija Sellami; Ferjani Zouidi; Raouia Fakhfakh; Nadia Mahfoudh; Hamida Turki; Hatem Masmoudi
Journal:  Mol Genet Genomic Med       Date:  2020-09-01       Impact factor: 2.183

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.